:max_bytes(150000):strip_icc():focal(717x224:719x226)/kelly-ripa-mark-consuelos-live-2-080525-9e98d41d17134c0c9b0dac66dac4cc7a.jpg)
Praxis Precision Medicines' ulixacaltamide achieves significant clinical results in two Phase 3 studies for essential tremor, offering hope for millions.
October 16, 2025
Source:
Praxis Medicines
Breakthrough Results for Essential Tremor Drug
Praxis Precision Medicines announced that its investigational drug ulixacaltamide met all primary and key secondary endpoints in two pivotal Phase 3 studies for essential tremor (ET). The trials, part of the Essential3 program, enrolled 473 adults and used a decentralized model with in-home and telehealth visits [BioPharma Dive].
Study Approach
Randomized, placebo-controlled, 12-week trials
Patient-centric design using validated daily living questionnaires
Measured functional improvement in self-care and daily tasks
Keep up with the story. Subscribe to the PR+ free daily newsletter
Source:
Getty Images
Key Findings From the Essential3 Trials
Ulixacaltamide provided a 4.3-point improvement in daily activities versus placebo at Week 8 (p<0.0001) [Applied Clinical Trials].
Benefits were sustained throughout the 12-week dosing period.
In the withdrawal part of the study, 55% of patients on the drug maintained response, compared to 33% on placebo.
Treatment Landscape
Essential tremor is the most common adult movement disorder, with limited treatments. The only current FDA-approved option, propranolol, has side effects like dizziness and fatigue and does not work for all [Neurology Journal].
Read More
Source:
Shutterstock
Share this news:
